섬유근육통 치료 시장 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of fibromyalgia treatment Market

The global fibromyalgia treatment market size was valued at USD 2.53 billion in 2025 and is projected to grow from USD 2.66 billion in 2026 to USD 4.02 billion by 2034, exhibiting a CAGR of 5.30% during the forecast period. North America dominated the fibromyalgia treatment market with a market share of 65.35% in 2025. Fibromyalgia is a musculoskeletal disorder primarily characterized by widespread pain, fatigue, sleep disturbances, mood changes, and memory problems. The market is supported by increasing disease prevalence, improving diagnosis, research and development activities, and the development of new treatment options.

The limited number of specifically approved medicines has resulted in substantial use of off-label and generic therapies for fibromyalgia management. However, increasing clinical research and development in pain management is supporting the development of potential new therapies. Pipeline products, product launches, improving healthcare access, and growing awareness of fibromyalgia are expected to create additional opportunities for market expansion during the forecast period.

Market Definition and Scope

Fibromyalgia treatment includes pharmaceutical therapies used to manage the symptoms associated with fibromyalgia, including chronic pain, fatigue, sleep disturbances, and related symptoms. The treatment landscape includes approved medicines as well as off-label therapies that may be used by healthcare professionals based on patient requirements.

The market is segmented by drug class into antidepressants, antiepileptic drugs, muscle relaxants, and others, including pipeline products. By distribution channel, the market includes hospital pharmacies, retail pharmacies, and online pharmacies. The report also examines regional markets, competitive developments, pipeline analysis, regulatory factors, and the impact of COVID-19.

Market Dynamics

Drivers

Increasing prevalence of fibromyalgia is a major factor supporting market growth. According to the supplied report, approximately five million adults in the U.S. suffer from fibromyalgia, with women representing a substantial proportion of diagnosed patients. Increasing awareness, diagnosis rates, healthcare expenditure, and government and medical organization initiatives are contributing to greater attention toward disease management.

Strong pipeline products and continued research are also expected to support the market. Pharmaceutical companies are investigating innovative therapies and evaluating existing medicines for potential fibromyalgia applications. Clinical research, new product authorizations, and improvements in pain-management technologies are creating opportunities for treatment expansion.

Trends

Mergers, acquisitions, product development, and expansion of existing therapies represent important market trends. Companies are increasingly evaluating established medicines for additional indications and investing in clinical trials for fibromyalgia. Growing interest in innovative therapies is expected to expand treatment choices for patients.

Restraints

The higher adoption of off-label and generic drugs can restrict revenue growth for specifically approved branded therapies. The market has historically had a limited number of medicines specifically approved for fibromyalgia, while generic competition following patent expirations can place additional pressure on branded product revenues.

Impact of COVID-19

The COVID-19 pandemic negatively affected the fibromyalgia treatment market as fewer patients sought treatment during lockdowns and healthcare resources were redirected toward COVID-19 medicines and vaccines. Pharmaceutical manufacturing and supply chains were also disrupted. Postponement of medical consultations and reduced treatment-seeking activity further affected demand. Recovery in healthcare services, pharmaceutical operations, diagnosis, and clinical research supported market normalization after the pandemic.

Segmentation Analysis

By drug class, antiepileptic drugs held a leading position in 2026, supported by strong adoption of established therapies such as Lyrica for fibromyalgia management. Antidepressants and muscle relaxants also represent important treatment categories, while pipeline products could influence the competitive structure.

By distribution channel, hospital pharmacies are expected to account for a 44.6% share in 2025. Retail pharmacies benefit from convenient access to medicines and the availability of over-the-counter products, while online pharmacies are gaining importance as digital healthcare distribution expands, particularly in developing markets.

Regional Insights

North America dominated the market, generating USD 1,253.5 million in revenue in 2025. High diagnosis rates, disease prevalence, availability of approved treatments, healthcare infrastructure, and continued pharmaceutical innovation are supporting regional growth.

Europe is anticipated to grow at a CAGR of 8.9% during the forecast period, supported by increasing prevalence, healthcare spending, limited treatment options, and potential product launches. Asia Pacific is expected to experience steady growth due to rising patient populations, healthcare expenditure, infrastructure development, and disease awareness. Japan's market is expected to reach USD 30.2 million by 2025, while China is projected to register a CAGR of 7.70%. Latin America and the Middle East & Africa are improving treatment availability through expanding public and private healthcare sectors.

Competitive Landscape

The market includes Pfizer, Inc., Eli Lilly and Company, Allergan, Tonix Pharmaceuticals, Aptinyx, Teva Pharmaceutical Industries Ltd., Novartis AG, Sun Pharmaceuticals, and Astellas Pharma Inc. Companies are focusing on clinical development, product launches, mergers and acquisitions, manufacturing expansion, and pipeline development.

Recent developments include Tonix Pharmaceuticals' FDA review of TNX-102 SL for fibromyalgia in February 2025. Lilly announced major U.S. manufacturing investments, while Novartis announced plans for additional U.S. manufacturing facilities. These developments reflect continued investment in pharmaceutical production and innovation.

Report Coverage

The fibromyalgia treatment market report covers 2025 to 2034 and provides market size and value data for 2025, 2026, and 2034. It analyzes drug classes, distribution channels, market dynamics, COVID-19 impact, regional performance, pipeline products, regulatory factors, competitive strategies, and key industry developments across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Conclusion

The global fibromyalgia treatment market was valued at USD 2.53 billion in 2025 and is projected to reach USD 2.66 billion in 2026 and USD 4.02 billion by 2034, registering a CAGR of 5.30%. Increasing prevalence, improved diagnosis, rising healthcare awareness, pharmaceutical research, pipeline therapies, and potential product launches are expected to support market growth. North America remains the dominant regional market, while Europe and Asia Pacific are expected to provide important growth opportunities during the forecast period.

Unit Value (USD Million)

Segmentation Drug Class, Distribution Channel, and Region

By Drug Class

• Antidepressants
• Antiepileptic
• Muscle Relaxants
• Others (incl. Pipeline Products)

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Geography

• North America
  • By Drug Class
  • By Distribution Channel
  • By Country
• USA (By Drug Class)
• Canada (By Drug Class)
• Europe
  • By Drug Class
  • By Distribution Channel
  • By Country
• UK (By Drug Class)
• Germany (By Drug Class)
• France (By Drug Class)
• Italy (By Drug Class)
• Spain (By Drug Class)
• Scandinavia (By Drug Class)
• Rest of Europe (By Drug Class)
• Asia Pacific
  • By Drug Class
  • By Distribution Channel
  • By Country
• Japan (By Drug Class)
• China (By Drug Class)
• India (By Drug Class)
• Australia (By Drug Class)
• Southeast Asia (By Drug Class)
• Rest of Asia Pacific (By Drug Class)
• Latin America
  • By Drug Class
  • By Distribution Channel
  • By Country
• Brazil (By Drug Class)
• Mexico (By Drug Class)
• Rest of Latin America (By Drug Class)
• Middle East & Africa
  • By Drug Class
  • By Distribution Channel
  • By Country
• GCC (By Drug Class)
• South Africa (By Drug Class)
• Rest of MEA (By Drug Class)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Prevalence of Fibromyalgia by key Regions
• 4.2. Key Industry Trends
• 4.3. Pipeline Analysis
• 4.4. Regulatory Scenario
• 4.5. Recent Industry Developments Such as Mergers & Acquisitions
• 4.6. Impact of COVID-19 on the Market

5. Global Fibromyalgia Treatment Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Drug Class
  • 5.2.1. Antidepressants
  • 5.2.2. Antiepileptic
  • 5.2.3. Muscle Relaxants
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.3.1. Hospital Pharmacy
  • 5.3.2. Retail Pharmacy
  • 5.3.3. Online Pharmacy
• 5.4. Market Analysis, Insights and Forecast - By Country
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Fibromyalgia Treatment Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis - By Drug Class
  • 6.2.1. Antidepressants
  • 6.2.2. Antiepileptic
  • 6.2.3. Muscle Relaxants
  • 6.2.4. Others
• 6.3. Market Analysis - By Distribution Channel
  • 6.3.1. Hospital Pharmacy
  • 6.3.2. Retail Pharmacy
  • 6.3.3. Online Pharmacy
• 6.4. Market Analysis - By Country
  • 6.4.1. U.S.
    • 6.4.1.1. By Drug Class
      • 6.4.1.1.1. Antidepressants
      • 6.4.1.1.2. Antiepileptic
      • 6.4.1.1.3. Muscle Relaxants
      • 6.4.1.1.4. Others
  • 6.4.2. Canada
    • 6.4.2.1. By Drug Class
      • 6.4.2.1.1. Antidepressants
      • 6.4.2.1.2. Antiepileptic
      • 6.4.2.1.3. Muscle Relaxants
      • 6.4.2.1.4. Others

7. Europe Fibromyalgia Treatment Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis - By Drug Class
  • 7.2.1. Antidepressants
  • 7.2.2. Antiepileptic
  • 7.2.3. Muscle Relaxants
  • 7.2.4. Others
• 7.3. Market Analysis - By Distribution Channel
  • 7.3.1. Hospital Pharmacy
  • 7.3.2. Retail Pharmacy
  • 7.3.3. Online Pharmacy
• 7.4. Market Analysis - By Country
  • 7.4.1. U.K.
    • 7.4.1.1. By Drug Class
      • 7.4.1.1.1. Antidepressants
      • 7.4.1.1.2. Antiepileptic
      • 7.4.1.1.3. Muscle Relaxants
      • 7.4.1.1.4. Others
  • 7.4.2. Germany
    • 7.4.2.1. By Drug Class
      • 7.4.2.1.1. Antidepressants
      • 7.4.2.1.2. Antiepileptic
      • 7.4.2.1.3. Muscle Relaxants
      • 7.4.2.1.4. Others
  • 7.4.3. France
    • 7.4.3.1. By Drug Class
      • 7.4.3.1.1. Antidepressants
      • 7.4.3.1.2. Antiepileptic
      • 7.4.3.1.3. Muscle Relaxants
      • 7.4.3.1.4. Others
  • 7.4.4. Spain
    • 7.4.4.1. By Drug Class
      • 7.4.4.1.1. Antidepressants
      • 7.4.4.1.2. Antiepileptic
      • 7.4.4.1.3. Muscle Relaxants
      • 7.4.4.1.4. Others
  • 7.4.5. Italy
    • 7.4.5.1. By Drug Class
      • 7.4.5.1.1. Antidepressants
      • 7.4.5.1.2. Antiepileptic
      • 7.4.5.1.3. Muscle Relaxants
      • 7.4.5.1.4. Others
  • 7.4.6. Scandinavia
    • 7.4.6.1. By Drug Class
      • 7.4.6.1.1. Antidepressants
      • 7.4.6.1.2. Antiepileptic
      • 7.4.6.1.3. Muscle Relaxants
      • 7.4.6.1.4. Others
  • 7.4.7. Rest of Europe
    • 7.4.7.1. By Drug Class
      • 7.4.7.1.1. Antidepressants
      • 7.4.7.1.2. Antiepileptic
      • 7.4.7.1.3. Muscle Relaxants
      • 7.4.7.1.4. Others

8. Asia Pacific Fibromyalgia Treatment Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis - By Drug Class
  • 8.2.1. Antidepressants
  • 8.2.2. Antiepileptic
  • 8.2.3. Muscle Relaxants
  • 8.2.4. Others
• 8.3. Market Analysis - By Distribution Channel
  • 8.3.1. Hospital Pharmacy
  • 8.3.2. Retail Pharmacy
  • 8.3.3. Online Pharmacy
• 8.4. Market Analysis - By Country
  • 8.4.1. Japan
    • 8.4.1.1. By Drug Class
      • 8.4.1.1.1. Antidepressants
      • 8.4.1.1.2. Antiepileptic
      • 8.4.1.1.3. Muscle Relaxants
      • 8.4.1.1.4. Others
  • 8.4.2. China
    • 8.4.2.1. By Drug Class
      • 8.4.2.1.1. Antidepressants
      • 8.4.2.1.2. Antiepileptic
      • 8.4.2.1.3. Muscle Relaxants
      • 8.4.2.1.4. Others
  • 8.4.3. India
    • 8.4.3.1. By Drug Class
      • 8.4.3.1.1. Antidepressants
      • 8.4.3.1.2. Antiepileptic
      • 8.4.3.1.3. Muscle Relaxants
      • 8.4.3.1.4. Others
  • 8.4.4. Australia
    • 8.4.4.1. By Drug Class
      • 8.4.4.1.1. Antidepressants
      • 8.4.4.1.2. Antiepileptic
      • 8.4.4.1.3. Muscle Relaxants
      • 8.4.4.1.4. Others
  • 8.4.5. Southeast Asia
    • 8.4.5.1. By Drug Class
      • 8.4.5.1.1. Antidepressants
      • 8.4.5.1.2. Antiepileptic
      • 8.4.5.1.3. Muscle Relaxants
      • 8.4.5.1.4. Others
  • 8.4.6. Rest of Asia Pacific
    • 8.4.6.1. By Drug Class
      • 8.4.6.1.1. Antidepressants
      • 8.4.6.1.2. Antiepileptic
      • 8.4.6.1.3. Muscle Relaxants
      • 8.4.6.1.4. Others

9. Latin America Fibromyalgia Treatment Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis - By Drug Class
  • 9.2.1. Antidepressants
  • 9.2.2. Antiepileptic
  • 9.2.3. Muscle Relaxants
  • 9.2.4. Others
• 9.3. Market Analysis - By Distribution Channel
  • 9.3.1. Hospital Pharmacy
  • 9.3.2. Retail Pharmacy
  • 9.3.3. Online Pharmacy
• 9.4. Market Analysis - By Country
  • 9.4.1. Brazil
    • 9.4.1.1. By Drug Class
      • 9.4.1.1.1. Antidepressants
      • 9.4.1.1.2. Antiepileptic
      • 9.4.1.1.3. Muscle Relaxants
      • 9.4.1.1.4. Others
  • 9.4.2. Mexico
    • 9.4.2.1. By Drug Class
      • 9.4.2.1.1. Antidepressants
      • 9.4.2.1.2. Antiepileptic
      • 9.4.2.1.3. Muscle Relaxants
      • 9.4.2.1.4. Others
  • 9.4.3. Rest of Latin America
    • 9.4.3.1. By Drug Class
      • 9.4.3.1.1. Antidepressants
      • 9.4.3.1.2. Antiepileptic
      • 9.4.3.1.3. Muscle Relaxants
      • 9.4.3.1.4. Others

10. Middle East & Africa Fibromyalgia Treatment Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Key Findings / Summary
• 10.2. Market Analysis - By Drug Class
  • 10.2.1. Antidepressants
  • 10.2.2. Antiepileptic
  • 10.2.3. Muscle Relaxants
  • 10.2.4. Others
• 10.3. Market Analysis - By Distribution Channel
  • 10.3.1. Hospital Pharmacy
  • 10.3.2. Retail Pharmacy
  • 10.3.3. Online Pharmacy
• 10.4. Market Analysis - By Country
  • 10.4.1. GCC
    • 10.4.1.1. By Drug Class
      • 10.4.1.1.1. Antidepressants
      • 10.4.1.1.2. Antiepileptic
      • 10.4.1.1.3. Muscle Relaxants
      • 10.4.1.1.4. Others
  • 10.4.2. South Africa
    • 10.4.2.1. By Drug Class
      • 10.4.2.1.1. Antidepressants
      • 10.4.2.1.2. Antiepileptic
      • 10.4.2.1.3. Muscle Relaxants
      • 10.4.2.1.4. Others
  • 10.4.3. Rest of Middle East & Africa
    • 10.4.3.1. By Drug Class
      • 10.4.3.1.1. Antidepressants
      • 10.4.3.1.2. Antiepileptic
      • 10.4.3.1.3. Muscle Relaxants
      • 10.4.3.1.4. Others

11. Competitive Analysis

• 11.1. Key Industry Developments
• 11.2. Global Market Share Analysis (2025)
• 11.3. Competition Dashboard
• 11.4. Comparative Analysis - Major Players
• 11.5. Company Profiles
  • 11.5.1. Pfizer, Inc.
    • 11.5.1.1. Overview,
    • 11.5.1.2. Products & services,
    • 11.5.1.3. SWOT analysis,
    • 11.5.1.4. Recent developments,
    • 11.5.1.5. strategies,
    • 11.5.1.6. financials (based on availability)
  • 11.5.2. Eli Lilly and Company
    • 11.5.2.1. Overview,
    • 11.5.2.2. Products & services,
    • 11.5.2.3. SWOT analysis,
    • 11.5.2.4. Recent developments,
    • 11.5.2.5. strategies,
    • 11.5.2.6. financials (based on availability)
  • 11.5.3. Allegran
    • 11.5.3.1. Overview,
    • 11.5.3.2. Products & services,
    • 11.5.3.3. SWOT analysis,
    • 11.5.3.4. Recent developments,
    • 11.5.3.5. strategies,
    • 11.5.3.6. financials (based on availability)
  • 11.5.4. Tonix Pharmaceuticals
    • 11.5.4.1. Overview,
    • 11.5.4.2. Products & services,
    • 11.5.4.3. SWOT analysis,
    • 11.5.4.4. Recent developments,
    • 11.5.4.5. strategies,
    • 11.5.4.6. financials (based on availability)
  • 11.5.5. Aptinyx
    • 11.5.5.1. Overview,
    • 11.5.5.2. Products & services,
    • 11.5.5.3. SWOT analysis,
    • 11.5.5.4. Recent developments,
    • 11.5.5.5. strategies,
    • 11.5.5.6. financials (based on availability)
  • 11.5.6. Teva Pharmaceutical Industries Ltd.
    • 11.5.6.1. Overview,
    • 11.5.6.2. Products & services,
    • 11.5.6.3. SWOT analysis,
    • 11.5.6.4. Recent developments,
    • 11.5.6.5. strategies,
    • 11.5.6.6. financials (based on availability)
  • 11.5.7. Novartis AG
    • 11.5.7.1. Overview,
    • 11.5.7.2. Products & services,
    • 11.5.7.3. SWOT analysis,
    • 11.5.7.4. Recent developments,
    • 11.5.7.5. strategies,
    • 11.5.7.6. financials (based on availability)
  • 11.5.8. Sun Pharmaceuticals
    • 11.5.8.1. Overview,
    • 11.5.8.2. Products & services,
    • 11.5.8.3. SWOT analysis,
    • 11.5.8.4. Recent developments,
    • 11.5.8.5. strategies,
    • 11.5.8.6. financials (based on availability)
  • 11.5.9. Astella Pharma Inc
    • 11.5.9.1. Overview,
    • 11.5.9.2. Products & services,
    • 11.5.9.3. SWOT analysis,
    • 11.5.9.4. Recent developments,
    • 11.5.9.5. strategies,
    • 11.5.9.6. financials (based on availability)
  • 11.5.10. Other Prominent Players
    • 11.5.10.1. Overview,
    • 11.5.10.2. Products & services,
    • 11.5.10.3. SWOT analysis,
    • 11.5.10.4. Recent developments,
    • 11.5.10.5. strategies,
    • 11.5.10.6. financials (based on availability)

12. Strategic Recommendations